Medicare Expansion for GLP-1 Agonists Balances Clinical Gains and Cost Risks
New analysis projects increased Medicare spending with expanded GLP-1 receptor agonist coverage for obesity, highlighting clinical benefits and financial challenges.
U.S. Pharmaceutical Regulation and Pricing: April 2025 Update
April 2025 update on U.S. pharmaceutical regulation highlights executive orders, budget changes, CMS policies, IRA litigation, and 340B program developments shaping drug pricing and access.